Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 14/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.37 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30495481 | 0.87 | ADORA2B (0.58) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL796431 | 0.87 | ADORA2B (0.58) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL1728530 | 0.87 | ADORA2B (0.42) | ADORA2BADORA2AADORA3ADORA1KLKB1 | |
| SCHEMBL1546641 | 0.86 | ADORA2B (0.56) | ADORA2BADORA2AADORA3ADORA1KLKB1 | |
| SCHEMBL1546784 | 0.86 | ADORA2B (0.41) | ADORA2BADORA2AADORA3ADORA1KLKB1 | |
| SCHEMBL1723697 | 0.84 | ADORA2B (0.52) | ADORA2BADORA2AADORA3ADORA1KLKB1 | |
| SCHEMBL8979404 | 0.84 | ADORA2B (0.49) | ADORA2BADORA2AADORA3ADORA1KLKB1 | |
| SCHEMBL1546781 | 0.81 | KLKB1 (0.52) | ADORA2BADORA2AADORA3ADORA1KLKB1 | |
| SCHEMBL1546106 | 0.77 | ADORA2B (0.58) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL5584758 | 0.76 | ROCK1 (0.39) | ADORA2BADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| EP-2405917-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2014-04-23 | — | — | EP | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA3 3/4885 |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.